Anti-Mouse IL-15 Antibody (AIO.3)

Cat. No.: HY-P990223 Purity: 95.00%: Data Sheet
COA

SDS

FAQs
Technical Support

Anti-Mouse IL-15 Antibody (AIO.3) is a rat-derived IgG2a, λ type antibody inhibitor, targeting to mouse IL-15.

For research use only. We do not sell to patients.

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anti-Mouse IL-15 Antibody (AIO.3) Featured Recommendations:

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Interleukin Related Isoform Specific Products:

View All Isoforms

IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

Biological Activity
Purity & Documentation
References
Customer Review

Description

Anti-Mouse IL-15 Antibody (AIO.3) is a rat-derived IgG2a, λ type antibody inhibitor, targeting to mouse IL-15.

Isotype

Rat IgG2a kappa

Recommend Isotype Controls

Rat IgG2a kappa, Isotype Control

IC₅₀ & Target

IL-15

In Vitro

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Anti-Mouse IL-15 Antibody (AIO.3) (25 µg/mouse, i.p., daily from from day -1 to day 2 of the infection) shows anti-infection effect by neutralizing IL-15 in mouse hepatitis virus infected mice models^[1].
Anti-Mouse IL-15 Antibody (AIO.3) (4 mg/kg, i.v., twice a week) is effective in preserving coagulation factor VIII expression and has broad anti-inflammatory effects in adeno-associated viral (AAV)-transduced hemophilia A mice^[2].
Anti-Mouse IL-15 Antibody (AIO.3) (300 µg/mouse, i.p., 3 times a week) ameliorates podocyte injury and glomerulosclerosis in Adriamycin (HY-121309)-induced focal segmental glomerulosclerosis mice models^[3].
Anti-Mouse IL-15 Antibody (AIO.3) (100 µg, i.v., at days 0, 4, 7, 11, 14, 18) reduces esophageal eosinophilia in experimental eosinophilic esophagitis mice models^[4].
Anti-Mouse IL-15 Antibody (AIO.3) (1 mg/kg, i.p., daily from day 5 to 11) reduces therapeutic effect in response to anti-CD40 agonist in intravesical tumor mice models^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse hepatitis virus infected mice models^[1]
Dosage:	25 µg/mouse
Administration:	Intraperitoneally injection, daily from from day -1 to day 2 of the infection
Result:	Efficiently blunted the exaggerated population expansion of group 1 ILCs in Myd88-cKO PPs. Led to a reduced frequency and absolute number of group 1 ILCs in Myd88-sufficient mice and diminished the ILC3 population both in Myd88-sufficient PPs and in Myd88-cKO PPs. Disinhibited viral replication in Myd88-cKO mice.

Animal Model:	Male hemophilia A mice with targeted deletion of F8 exon 16 (6-8 weeks)^[2]
Dosage:	4 mg/kg
Administration:	Intravenously injection, twice a week, combined with rapamycin (HY-10219)
Result:	Preserved hFVIII expression. Resulted in significantly higher average FVIII activity by week 16. Had modestly increased NK cell frequencies and moderately decreased CD8+ Teff cells. Increased expression of CD206. Had elevated p-eIF2a and IFN-γ transcripts.

Animal Model:	Adriamycin (HY-121309)-induced focal segmental glomerulosclerosis mice models^[3]
Dosage:	300 µg /mouse
Administration:	Intraperitoneally injection, 3 times a week
Result:	Significantly inhibited renal CD8+ TRM cell formation and activation. Showed lower UACR and fewer glomerular and podocyte injuries. Recovered the expressions of nephrin and podocin.

Animal Model:	Experimental eosinophilic esophagitis mice models^[4]
Dosage:	100 µg
Administration:	Intravenously injection , at days 0, 4, 7, 11, 14, 18
Result:	Reduced esophageal eosinophilia.

Gene ID

16168 [NCBI]

Accession

P48346

Application

ELISA, FACS, Functional assay, Research in vivo

Conjugated

Unconjugated

Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.

Molecular Weight

150 kDa

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Anti-Mouse IL-15 Antibody (AIO.3)]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Biological Activity

Immobilized IL-15 Protein, Mouse (HEK293, Fc, HY-P78719) can bind Anti-Mouse IL-15 Antibody (AIO.3). The EC₅₀ for this effect is 62.13 ng/mL.

Purity & Documentation

Purity: 95.00%

Select Batch:

Data Sheet (266 KB) SDS (251 KB)

COA (232 KB)

Inhibitory Antibodies User Guide (602 KB)

References

[1]. Gil-Cruz C, et al. Fibroblastic reticular cells regulate intestinal inflammation via IL-15-mediated control of group 1 ILCs. Nat Immunol. 2016 Dec;17(12):1388-1396. [Content Brief]

[2]. Butterfield JSS, et al. IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice. Mol Ther. 2022 Dec 7;30(12):3552-3569. [Content Brief]

[3]. Li L, et al. Targeting tissue-resident memory CD8+ T cells in the kidney is a potential therapeutic strategy to ameliorate podocyte injury and glomerulosclerosis. Mol Ther. 2022 Aug 3;30(8):2746-2759. [Content Brief]

[4]. Vicari AP, et al. Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis. MAbs. 2017 Aug/Sep;9(6):927-944. [Content Brief]

[5]. Wong JL, et al. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer. Proc Natl Acad Sci U S A. 2023 Aug 29;120(35):e2306782120. [Content Brief]

Anti-Mouse IL-15 Antibody (AIO.3) Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anti-Mouse IL-15 Antibody (AIO.3)Interleukin RelatedILIL-15CancerHepatitis virusEsophagitisGlomerulosclerosisAdeno-associated viralInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks